A citation-based method for searching scientific literature

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List. Diabetes Obes Metab 2013
Times Cited: 472



Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease.
Hiddo J L Heerspink, Paul Perco, Skander Mulder, Johannes Leierer, Michael K Hansen, Andreas Heinzel, Gert Mayer. Diabetologia 2019
Times Cited: 139




List of shared articles



Times cited

Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease.
Hongyan Liu, Vikas S Sridhar, Jacinthe Boulet, Atit Dharia, Abid Khan, Patrick R Lawler, David Z I Cherney. Metabolism 2022
3

Renoprotective mechanisms of sodium-glucose co-transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease.
Sreenithya Ravindran, Shankar Munusamy. J Cell Physiol 2022
2

Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: A meta-analysis.
Qi Tian, Keyu Guo, Jiayi Deng, Yanjun Zhong, Lin Yang. J Cell Mol Med 2022
1

Interaction between sodium-glucose co-transporter 2 and the sympathetic nervous system.
Omar Azzam, Vance B Matthews, Markus P Schlaich. Curr Opin Nephrol Hypertens 2022
1

Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk Markers.
Sok Cin Tye, Sieta T de Vries, Christoph Wanner, Petra Denig, Hiddo J L Heerspink. Front Pharmacol 2022
2

Beneficial cardiovascular and remodeling effects of SGLT 2 inhibitors.
Steven G Chrysant, George S Chrysant. Expert Rev Cardiovasc Ther 2022
0

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.
Teresa Salvatore, Raffaele Galiero, Alfredo Caturano, Luca Rinaldi, Anna Di Martino, Gaetana Albanese, Jessica Di Salvo, Raffaella Epifani, Raffaele Marfella, Giovanni Docimo,[...]. Int J Mol Sci 2022
0

Sodium-Glucose Cotransporter-2 Inhibitors Improve Heart Failure with Reduced Ejection Fraction Outcomes by Reducing Edema and Congestion.
Michelle Hernandez, Ryan D Sullivan, Mariana E McCune, Guy L Reed, Inna P Gladysheva. Diagnostics (Basel) 2022
1

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Katherine R Tuttle, Frank C Brosius, Matthew A Cavender, Paola Fioretto, Kevin J Fowler, Hiddo J L Heerspink, Tom Manley, Darren K McGuire, Mark E Molitch, Amy K Mottl,[...]. Diabetes 2021
17

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Katherine R Tuttle, Frank C Brosius, Matthew A Cavender, Paola Fioretto, Kevin J Fowler, Hiddo J L Heerspink, Tom Manley, Darren K McGuire, Mark E Molitch, Amy K Mottl,[...]. Am J Kidney Dis 2021
37

Sodium-Glucose Co-Transporter 2 Inhibitors and Insights from Biomarker Measurement in Heart Failure Patients.
Nasrien E Ibrahim, James L Januzzi. Clin Chem 2021
1

A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors.
Taha Sen, Hiddo J L Heerspink. Cell Metab 2021
22

Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics.
Zhenghong Liu, Xiaoxuan Ma, Iqra Ilyas, Xueying Zheng, Sihui Luo, Peter J Little, Danielle Kamato, Amirhossein Sahebkar, Weiming Wu, Jianping Weng,[...]. Theranostics 2021
17

Reno-protective potential of sodium glucose cotransporter-2 (SGLT2) inhibitors: Summary evidence from clinical and real-world data.
Niti Mittal, Vikas Sehray, Rakesh Mittal, Surjit Singh. Eur J Pharmacol 2021
2


Longstocking, LLC. © 2021
Home | About Us | FAQs | Terms & Privacy